Overview
Skyhawk Therapeutics develops small molecule therapeutics that modify RNA expression, aiming to treat diseases that are hard to address with conventional drugs. Using the SKYSTAR platform and proprietary structural, kinetic, and computational models, the company designs compounds that influence RNA splicing and expression; SKY-0515 is one such RNA splicing modifier at the center of their pipeline. Their product works by binding to RNA or the splicing machinery with small molecules to alter RNA outcomes, differentiating their approach from traditional protein-targeted therapies. The company’s competitive edge comes from its integrated platform and data-driven design tools that enable targeted RNA modulation, potentially enabling therapies for previously intractable diseases. Skyhawk’s goal is to research, develop, and commercialize RNA-targeting small molecules, progressing compounds through clinical trials toward approval and use by healthcare providers and patients.
Work here?Claim your company